What InfectoPharm does

InfectoPharm Arzneimittel und Consilium GmbH is a privately-held, family-owned German pharmaceutical company founded in 1988 in Heppenheim by Monika and Dr. Manfred Zöller, now in its second generation of family control under Chairman Philipp Zöller. The company specializes in the development and distribution of pediatric and specialty medications, with a portfolio of more than 130 products spanning prescription pharmaceuticals (Rx), over-the-counter products (OTC), medical devices, and cosmetics across five therapeutic areas: pediatrics, hospital infectious diseases (specialty antibiotics including InfectoFos, Gernebcin, Penicillin G, and Mupirocin), dermatology (atopic dermatitis, acne, scabies), pneumology/asthma, and ENT medicine.

Its core technology is proprietary pharmaceutical formulation expertise, particularly child-friendly dosage forms (liquids, mini-tablets, gels) with improved taste, age-appropriate delivery systems (e.g., the first oral salbutamol for infants from 2 months old, dexamethasone juice for croup), and resistance-fighting antibiotics for hospital use. The company operates an in-house manufacturing subsidiary (Beyvers GmbH), a wholly-owned OTC subsidiary (Pädia GmbH, ~25 pediatric products), and a digital health subsidiary (Sonormed GmbH), plus a non-commercial scientific service called consilium that trains up to 6,000 healthcare professionals annually through CME-accredited courses, publications, and a flagship annual symposium attended by ~1,000 pediatricians.

InfectoPharm generates revenue primarily through B2B wholesale distribution to pharmaceutical wholesalers, hospitals, and pharmacies across six European countries (Germany, Austria, Italy, France, Poland, United Kingdom), with international business contributing approximately 25% of total revenue. Secondary revenue streams include licensing royalties (notably Winlevi/clascoterone in partnership with Cosmo Pharmaceuticals, launching June 2026 across 20 European markets), in-licensed and out-licensed products, and contract manufacturing. Pricing is not publicly disclosed but operates on standard B2B terms (net 30 days, 0.75% SEPA discount for 10-day payment, free shipping for orders ≥€300 net in Germany). The company reports approximately €250 million in annual sales with 400+ employees, has grown organically without external venture or private equity capital, and has expanded consistently at roughly 15% per year over the past decade.

Name

InfectoPharm

Legal name

InfectoPharm Arzneimittel und Consilium GmbH

Website

https://infectopharm.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

251–500 employees

Short description

InfectoPharm is a German family-owned pharmaceutical company founded in 1988 that develops and distributes pediatric and specialty medications (prescription, OTC, medical devices) across dermatology, infectious disease, pneumology, and ENT, serving wholesalers, hospitals, and physicians in six European countries with ~€250M in annual revenue.

Ownership category

akta.pro rank

Product category

Pediatric Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Pediatric Infectious Disease (HLAKAGAE)

akta.pro secondary industries

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Pediatric pharmaceuticals
• Prescription medications
• Hospital antibiotics
• Dermatology medications
• Pharmaceutical manufacturing

Headquarters

HQ city

Heppenheim

HQ country

Germany

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceuticals: Sale of prescription medications for pediatrics, hospital care, dermatology, pneumology, and other therapeutic areas. Products include antibiotics, asthma treatments, dermatology products, and specialty medications.
2. Over-the-Counter (OTC) Products: Sale of non-prescription medications and medical devices through pharmacies. Includes products for children and general consumer use in dermatology, respiratory, and other areas.
3. Licensing and Distribution: Revenue from licensing agreements for products like Winlevi (clascoterone) in Germany, Italy, and Austria, where InfectoPharm commercializes products developed by partners like Cosmo Pharmaceuticals.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels6 records

Core offering

InfectoPharm develops, manufactures, and distributes pharmaceutical products specializing in pediatrics, dermatology, pneumology, infectious diseases, ENT, and mental health. The portfolio includes over 130 products ranging from prescription medications and hospital antibiotics to over-the-counter products, medical devices, and cosmetics, with a focus on child-friendly formulations such as juices, syrups, and mini-tablets. The company also engages in in-licensing and out-licensing partnerships and operates the consilium scientific training service for healthcare professionals.

Product overview

InfectoPharm is a German family-owned pharmaceutical company founded in 1988, specializing in the development and distribution of pediatric and hospital medications. The company operates a diverse portfolio of more than 130 products across multiple therapeutic areas including pediatrics, dermatology, infectious diseases, pneumology, and ENT medicine. Their portfolio comprises prescription medications (Rx), over-the-counter products (OTC), medical devices, and cosmetics. Key product categories include: Hospital antibiotics (InfectoFos, Gernebcin, Penicillin G, Mupirocin Nasal Ointment), Pediatric medications (Capval, InfectoDexaKrupp, Naproxen Syrup, Salbubronch), Pediatric/Retail OTC products (Babybene Gel, Dimet 20, InfectoDell, Kinderlax, Neuroderm line, PädiaSalin, Lomaherpan, Lomaprotect, Psoribene), and Retail Rx medications (InfectoScab, Pendysin). The company also distributes Winlevi® (clascoterone) through partnership with Cosmo Pharmaceuticals. Subsidiaries include Pädia GmbH (OTC pediatric products) and Beyvers GmbH (contract manufacturing).

Differentiator

Problem solved

Functional benefit

Brands

• consilium: Interdisciplinary educational and consulting medical service for healthcare professionals; provides training courses and scientific publications without commercial interests
• InKi
• InfectoGreen

Products and services

• InfectoFos (Fosfomycin) Intravenous fosfomycin antibiotic for hospital use treating skin/soft tissue infections, osteomyelitis, respiratory infections, meningitis, MRSA, and P. aeruginosa in patients with multiresistant pathogens.
• Gernebcin (Tobramycin) Tobramycin product for hospital treatment of cystic fibrosis via inhalation, IV, and IM routes for severe gram-negative infections including nosocomial pneumonia, sepsis, endocarditis, and meningitis. Approved for children under 6 years.
• Penicillin G InfectoPharm Benzylpenicillin-Sodium (Penicillin G) for hospital treatment of erysipelas, streptococcal infections, and community-acquired pneumonia. Approved for use in newborns, infants, and during pregnancy and lactation.
• Mupirocin 2% Nasal Ointment Mupirocin calcium 2% ointment for nasal eradication of methicillin-resistant S. aureus (MRSA) colonization in adult patients and healthcare workers.
• Capval (Noscapin Cough Syrup) Noscapin-based cough suppressant for pediatricians and GPs. Effective opioid-equivalent cough suppression without narcotic side effects.
• InfectoDexaKrupp (Dexamethasone Juice) Dexamethasone liquid formulation for croup treatment (swelling of upper respiratory tracts below glottis). Features fast onset of action after 10 minutes with gentle, precise body weight-based dosing.
• Naproxen Syrup Naproxen 250mg/5ml oral liquid for treatment of painful conditions including arthritis, sprains, backache, menstrual pain, gout pain, and juvenile arthritis. Unique oral liquid formulation with only 2 intakes per day.
• SalbuBronch Elixier (Salbutamol) Salbutamol oral formulation for bronchitis and asthma treatment. Unique oral formulation for infants not able to use inhaler devices, registered for children from 2 months old.
• InfectoScab (Permethrin 5%) Permethrin 5% prescription medication for treatment of scabies. Single overnight application with excellent tolerance, approved from 2 months old.
• Pendysin (Benzylpenicillin-Benzathin) Benzylpenicillin-Benzathin with Lidocain for treatment of chronic streptococcal disease (rheumatic fever) and syphilis. First choice treatment for syphilis.
• Babybene Gel Macadamia/olive/jojoba oils-based cosmetic gel for natural cradle cap care in infants. Unique gel formulation that rinses off with water only.
• Dimet 20 (Head Lice Treatment) Medical device containing Dimethicone and Dodecanol for head lice treatment with a 20-minute treatment time and no resistance development.
• InfectoDell (Molluscum Treatment) Medical device containing Potassium hydroxide for painless treatment of Molluscum Contagiosum with excellent tolerance and clinically proven efficacy.
• Kinderlax (Macrogol 4000) Medical device containing Macrogol 4000 for constipation relief in children from 6 months to 12 years. Electrolyte-free formula mixable with juices with fewer side effects than lactulose.
• Lomaherpan (Melissa Extract Cream) Melissa Extract 0.05g cosmetic for treatment of herpes labialis. Natural antiviral with same efficacy as Aciclovir and no resistance problems.
• Neuroderm Skin Care Line Dermatological cosmetic line (Neuroderm Basic Skin Care and Neuroderm Repair) with glycerol and ceramides for maintenance treatment of atopic dermatitis, psoriasis, ichthyosis, and skin barrier repair.
• Otodolor Express (Ear Drops) Medical device containing Glycerol for irritation of external auditory canal and otitis externa. Preservative-free ear drops approved from birth that remove swelling and pain through osmosis.
• PädiaSalin (Saline Solutions) Sterile sodium chloride solutions (0.9% and 3%) in preservative-free ready-to-use plastic ampoules for respiratory mucus mobilization in bronchiolitis, bronchitis, and cystic fibrosis.
• Psoribene (Psoriasis Gel) Medical device containing olive and jojoba oil for symptomatic treatment of dandruff in psoriasis patients. Gel formulation rinses with water with no oily residue.
• Winlevi (Clascoterone 1% Cream) Clascoterone 1% cream for topical acne treatment, distributed in Germany, Austria, Italy, and 20+ European markets through partnership with Cosmo Pharmaceuticals. First-in-class topical androgen-receptor inhibitor.
• Lomaprotect (SPF 30 Lip Balm) Melissa Extract 0.05g cosmetic for prevention of herpes labialis with SPF 30 sun protection. Natural lip protection against herpes outbreaks.

Quantifiable outcome

• Over 40 percent of bacterial infections in hospitalized newborns are resistant to standard treatments
• +1 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• Cosmo Pharmaceuticals / CassiopeacoreChannel Partner/ Reseller/ Distributor · 1 June 2026License and distribution agreement for Winlevi (clascoterone 1% cream) acne treatment in Germany, Italy and Austria. Cosmo responsible for Centralized Marketing Authorization in EMA and exclusive product supply. InfectoPharm received Euro 1 million upfront payment, potential regulatory milestones up to Euro 4.5 million, and double-digit royalties on net sales. Product launched June 1, 2026 in Austria and Germany with rollout across 20 European markets.
• Global Antibiotic Research and Development Partnership (GARDP)coreStrategic or Co-development Partner · 9 July 2021Partnership to develop improved treatment options using combinations of existing antibiotics for neonatal sepsis. GARDP identified fosfomycin, flomoxef and amikacin as potential alternatives to ampicillin-gentamicin. InfectoPharm supporting study through provision of fosfomycin (InfectoFos/Fomicyt). Data to be provided to WHO for future treatment recommendations.
• Beyvers GmbHcoreOthersOwn contract manufacturing subsidiary in Berlin for domestic production. Full service supplier for pharmaceuticals and cosmetics.
• Pädia GmbHcoreOthers100% owned subsidiary developing over-the-counter (OTC) medications for children. Portfolio of about 25 prescription-free pharmaceuticals. Focuses on newborns and infants with motto Health from the very beginning.
• Sonormed GmbHminorOthersSubsidiary with digital health application within InfectoPharm Group.

Scale indicators8 records

Recent moves14 records

Expansion highlights6 records

Broad incumbents

• Pierre Fabre Group: French dermatology and family-owned pharma major relevant as InfectoPharm opens its Lyon office. Overlaps in dermatology (atopic dermatitis, scabies) and pediatrics, though significantly larger and more diversified.
• Stada Arzneimittel AG: Large German specialty pharma with broad OTC and pediatric portfolios across Europe. Overlaps with InfectoPharm's respiratory, dermatology and pediatric OTC categories but at much greater scale and breadth.

Direct peers

• Angelini Pharma: Privately-held European pharma with established pediatric and dermatology franchises. Italian ownership makes the pair geographically comparable as InfectoPharm expands via its Milan branch.
• Medice Arzneimittel Pütter: German family-owned specialty pharmaceutical company with a comparable focus on pediatric and neurology formulations (including ADHD portfolio). Direct competition for pediatrician relationships in German-speaking markets.
• Dr. Pfleger Arzneimittel: Bavaria-based family-owned German specialty pharma with overlapping pediatric, urology and dermatology portfolio - and historically a small player with in-licensing and German wholesaler-centric distribution.
• Chiesi Farmaceutici: Italian family-owned specialty pharma with a strong neonatology, pediatric and respiratory franchise (e.g. asthma/CF) and a growing in-licensing model. Most relevant European pediatric-focused peer for products like SalbuBronch and Gernebcin.
• Dermapharm Holding SE: German specialty pharma focused on dermatology, allergy and pediatrics, including branded generics and in-licensing. Comparable in its B2B pharmacy/wholesaler model and dermatology-franchise overlap.
• Pohl-Boskamp: German family-owned pharma specialist (now part of the Klosterfrau group) with similar size (~400 employees, niche specialty focus) and pediatric/respiratory portfolio overlap.
• Wörwag Pharma: German family-owned specialty pharma with similar revenue scale and a focus on neurological, dermatology and metabolic products distributed through German wholesalers and international subsidiaries.

Emerging players

• ALK-Abelló A/S: Danish allergy specialty pharma comparable in pediatric respiratory/allergy focus (allergoid immunotherapy) and similar size of European footprint. Overlaps in pediatric allergology where InfectoPharm promotes allergy products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/infectopharm-arzneimittel-und-consilium-gmbh

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InfectoPharm